Omeros Corp
OMER4.260USD
+0.200+4.93%
收盘 09/18, 16:00（美东）报价延迟15分钟
255.70M总市值
亏损市盈率 TTM
关于 Omeros Corp 公司
Omeros Corporation 是一家生物制药公司。该公司专注于发现、开发和商业化小分子和蛋白质疗法，用于治疗免疫疾病（包括补体介导的疾病、癌症以及成瘾和强迫症）的大市场和孤儿适应症。其主要 MASP-2 抑制剂 narsoplimab 靶向补体的凝集素途径，是 FDA 正在等待批准的生物制剂许可申请的主题，用于治疗造血干细胞移植相关的血栓性微血管病。其长效 MASP-2 抑制剂 OMS1029 正处于 I 期多剂量递增临床试验中。其 MASP-3 抑制剂 OMS906 是补体替代途径的关键激活剂，正在阵发性睡眠性血红蛋白尿和补体 3 肾小球病的临床项目中取得进展。该公司的主要磷酸二酯酶 7 抑制剂 OMS527 目前正在进行治疗可卡因使用障碍的临床开发。
公司简介
公司代码OMER
公司名称Omeros Corp
上市日期Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
员工数量202
证券类型Ordinary Share
年结日Oct 08
公司地址201 Elliott Avenue West
城市SEATTLE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编98119
电话12066765000
网址https://www.omeros.com/
公司代码OMER
上市日期Oct 08, 2009
CEODR. Gregory A. Demopulos, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
Dr. Thomas F. Bumol, Ph.D.
Dr. Thomas F. Bumol, Ph.D.
Independent Director
Independent Director
--
--
Dr. Catherine A. Melfi, Ph.D.
Dr. Catherine A. Melfi, Ph.D.
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
Vice President - Regulatory Affairs and Quality Systems, Chief Regulatory Officer
--
--
DR. Gregory A. Demopulos, M.D.
DR. Gregory A. Demopulos, M.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. David J. Borges
Mr. David J. Borges
Chief Accounting Officer, Vice President - Finance, Treasurer
Chief Accounting Officer, Vice President - Finance, Treasurer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Peter A. Demopulos, M.D.
Dr. Peter A. Demopulos, M.D.
Director
Director
372.90K
--
Dr. Leroy E. Hood, M.D., Ph.D.
Dr. Leroy E. Hood, M.D., Ph.D.
Independent Director
Independent Director
74.39K
--
Mr. Thomas J. Cable
Mr. Thomas J. Cable
Lead Independent Director
Lead Independent Director
35.07K
--
Mr. Arnold C. Hanish, CPA
Mr. Arnold C. Hanish, CPA
Independent Director
Independent Director
12.40K
--
Dr. Mariana N. Dimitrova, Ph.D.
Dr. Mariana N. Dimitrova, Ph.D.
Vice President - Chemistry, Manufacturing and Controls
Vice President - Chemistry, Manufacturing and Controls
--
--
Mr. Peter B. Cancelmo, J.D.
Mr. Peter B. Cancelmo, J.D.
Vice President, General Counsel, Secretary
Vice President, General Counsel, Secretary
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月17日 周日
更新时间: 8月17日 周日
持股股东
股东类型
持股股东
持股股东
占比
Ingalls & Snyder LLC (Asset Management)
5.85%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
2.98%
D. E. Shaw & Co., L.P.
2.42%
其他
78.50%
持股股东
持股股东
占比
Ingalls & Snyder LLC (Asset Management)
5.85%
BlackRock Institutional Trust Company, N.A.
5.43%
The Vanguard Group, Inc.
4.82%
Demopulos (Gregory A. M.D.)
2.98%
D. E. Shaw & Co., L.P.
2.42%
其他
78.50%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
16.49%
Investment Advisor
15.24%
Hedge Fund
6.07%
Research Firm
3.79%
Individual Investor
3.79%
Bank and Trust
0.88%
Insurance Company
0.12%
Venture Capital
0.09%
Pension Fund
0.05%
其他
53.47%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
255
30.16M
44.94%
-422.08K
2025Q1
263
30.38M
51.89%
-522.27K
2024Q4
256
29.32M
50.59%
-441.66K
2024Q3
242
27.89M
48.13%
-1.92M
2024Q2
248
27.65M
47.72%
-3.10M
2024Q1
269
28.11M
48.16%
-3.03M
2023Q4
275
27.52M
43.79%
-6.21M
2023Q3
299
30.25M
48.14%
-4.77M
2023Q2
303
29.52M
46.99%
+306.67K
2023Q1
308
23.79M
37.88%
-4.75M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Ingalls & Snyder LLC (Asset Management)
3.98M
6.79%
-30.05K
-0.75%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.02M
6.87%
+58.15K
+1.47%
Mar 31, 2025
The Vanguard Group, Inc.
3.24M
5.53%
+95.60K
+3.04%
Mar 31, 2025
Demopulos (Gregory A. M.D.)
2.03M
3.46%
--
--
May 23, 2025
D. E. Shaw & Co., L.P.
1.94M
3.31%
+99.63K
+5.42%
Mar 31, 2025
Stifel, Nicolaus & Company, Incorporated
1.56M
2.66%
-24.56K
-1.55%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.37M
2.34%
+29.70K
+2.22%
Mar 31, 2025
State Street Global Advisors (US)
1.36M
2.31%
+144.57K
+11.93%
Mar 31, 2025
Morgan Stanley & Co. LLC
584.71K
1%
+376.03K
+180.19%
Mar 31, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
